World-First Cancer Vaccine Cuts Melanoma Recurrence or Death Risk by 42% in Landmark Trial - ScienceAlert

World-First Cancer Vaccine Cuts Melanoma Recurrence or Death Risk by 42% in Landmark Trial ScienceAlertFirst-of-Its-Kind Vaccine Ushers in New Hope for Cancer Patients The New York TimesHow Melanoma Became the Proving Ground for a Personalized Cancer Vaccine Bloomberg.comModerna Investors Should Brace for More Whiplash WSJ#ESMO26: Merck and Moderna’s cancer vaccine data were ‘a triumph of science.’ And now, the work begins Endpoints News